drug

LY4050784

1 story · latest Oct 1, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Eli Lilly

Timeline

Foghorn and Lilly halt FHD-909 program, company cuts 40% of workforce

Oct 1PartnershipEli Lilly Foghorn Therapeutics Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.